**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 22188**

**Manuscript Type: LETTER TO THE EDITOR**

**Liuweiwuling tablets protect against acetaminophen hepatotoxicity: What is the protective mechanism?**

Du K *et al.* Liuweiwuling and acetaminophen hepatotoxicity

Kuo Du, Hartmut Jaeschke

**Kuo Du, Hartmut Jaeschke**, Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, United States

**Author contributions:** Du K wrote this letter; Jaeschke H revised the letter.

**Supported by** grants from the National Institutes of Health (R01 DK102142 and R01 AA12916); and the National Institute of General Medical Sciences (8 P20 GM103549-07) of the National Institutes of Health.

**Conflict-of-interest** **statement:** The authors declare no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Hartmut Jaeschke, PhD, ATS**, Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, 3901 Rainbow Blvd., MS 1018, Kansas City, KS 66160, United States. [hjaeschke@kumc.edu](mailto:hjaeschke@kumc.edu)

**Telephone:** +1-913-5887969

**Fax:** +1-913-5887501

**Received:** August 19, 2015

**Peer-review started:** August 20, 2015

**First decision:** September 19, 2015

**Revised:** September 29, 2015

**Accepted:** December 8, 2015

**Article in press:**

**Published online:**

**Abstract**

Study of the effects of natural products, including traditional Chinese Medicines, on acetaminophen hepatotoxicity has gained considerable popularity in recent years, and some of them showed positive results and even promising therapeutic potentials. A recent report suggested that Liuweiwuling tablets protect against acetaminophen hepatotoxicity and promote liver regeneration in a rodent model through alleviating the inflammatory response. However, several concerns exist regarding the limitations of the experimental design and interpretation of the data presented in this manuscript.

**Key words:** Acetaminophen hepatotoxicity; Liuweiwuling; sterile inflammation; natural products; liver regeneration

© **The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights

reserved.

**Core tip:** The reduced inflammatory response and the increased liver regeneration by Liuweiwuling treatment is more likely a secondary effect of the protection by inhibition of metabolic activation of acetaminophen rather than the primary mechanism of protection.

Du K, Jaeschke H. Liuweiwuling tablets protect against acetaminophen hepatotoxicity: What is the protective mechanism? *World J Gastroenterol* 2015; In press

**TO THE EDITOR**

We read with interest a recent article published by Lei *et al*[1]in which the authors concluded that Liuweiwuling tablets alleviate acetaminophen (APAP) hepatotoxicity by inhibiting the inflammatory response in mice[1]. The supporting evidence shown by the authors is the correlation between decreased levels of high-mobility group box 1 (HMGB1) protein and inflammatory cytokines (TNF-α, IL-1β) and the reduced liver injury after Liuweiwuling treatment. However, there are a number of concerns with the interpretation of the data and the mechanistic conclusions.

First, one of the main concerns is the relevance of the inflammatory response for APAP-induced liver injury. It is generally recognized that the initial necrotic cell death after APAP overdose results in the release of damage-associated molecular patterns (DAMPs), which bind to toll-like receptors (TLRs) on Kupffer cells and other inflammatory cells, and subsequently trigger the expression and release of pro-inflammatory cytokines[2]. This leads to the activation and hepatic recruitment of innate immune cells[2]. HMGB1 is one of such DAMPs that are released into the plasma after APAP overdose[3]. However, its contribution to the injury mechanisms has been controversial. While in one study antibodies against HMGB1 were shown to drastically reduce APAP toxicity[4], other authors reported only a minor reduction in liver injury or even no effect[5,6]. HMGB1 acts on Kupffer cells through TLR4 and induces expression of pro-inflammatory cytokines such as TNF-α and IL-1β. The role of TNF-α in APAP toxicity has also been controversial. An early study suggested that TNF-α promotes APAP toxicity[7]. However, other studies showed that mice deficient in TNF-α or TNF receptor-1are not protected, and an increase in hepatic TNF-α concentration does not worsen the liver injury but might actually prime hepatocytes to facilitate the following liver regeneration[8-10]. IL-1β is also induced and released after TLR4 and Nalp3 inflammasome activation. However, the minor amount of IL-1β generated during APAP hepatotoxicity has no impact on the injury process, and even 10000-fold higher IL-1β levels cannot affect the liver injury[11]. In addition, the fact that IL-1receptor-deficient mice are not protected from the injury clearly indicates that IL-1β signaling is not involved in the liver injury process[11,12]. Immune cells, such as neutrophils and macrophages, are recruited into the liver and are being activated during or after the peak of the liver injury (≥ 12 h post-APAP in mice and ≥ 2 d in patients) by these pro-inflammatory mediators[2,13]. However, extensive studies showed that immune cells are predominantly beneficial by removing cell debris and promoting liver regeneration rather than causing the liver injury[2]. Also, it is very unlikely the late infiltrating cells could be responsible for the ~80% reduction of liver injury during the first 6 h post-APAP[1]. In general, it takes at least 12 h before a neutrophil aggravates liver injury during a sterile inflammatory response[14]. Taken together, there is no convincing evidence that these pro-inflammatory mediators or recruited innate immune cells could result in direct cell death after APAP hepatotoxicity, and the inflammatory response more likely promotes the recovery process rather than aggravates the initial liver injury[2].

Second, it is well established that APAP hepatotoxicity is initiated by the cytochrome P450-catalyzed formation of the reactive metabolite *N*-acetyl-*p*-benzoquinone imine (NAPQI)[15]. Therefore, any interference with this initial step would have profound effects on the intracellular signaling mechanisms of APAP-induced cell death and the following inflammatory response. Thus, it is essential to determine whether a natural product or any other compound has any effects on this initial step before other protective mechanisms can be proposed[15,16]. Considering the facts that Liuweiwuling is given for 3 d before APAP at an extremely high dose (10.0 g/kg, 2 times/d by lavage) and the dramatic reduction of liver injury as early as 6 h when there is limited immune cell recruitment into the liver and no evidence that these cells are actually activated[17], it is likely that Liuweiwuling tablets protect against the toxicity simply by inhibiting the metabolic activation of APAP. In fact, some of the components of Liuweiwuling tablets[18], *e.g*., varies schisandra lignans, have been shown to be effective inhibitors of Cyp 2E1 and Cyp1A2[19], which are the critical enzymes for the metabolic activation of APAP[15,16]. If the initial step of NAPQI formation is inhibited resulting in dramatically attenuated cell death, the reduced formation of inflammatory mediators is merely the consequence of the reduced early necrosis rather than the cause. Actually, inattention to this issue has led to misinterpretation of experimental results and mistaken conclusions in many APAP studies in recent years[19-23].

The third concern comes from the effect of Liuweiwuling tablets on liver regeneration. It is known that severe liver injury after APAP overdose inhibits liver regeneration because of the active inhibition of cell cycle progression, while a more moderate liver injury triggers a prompt and vigorous regeneration response[24,25]. Since the liver injury was largely reduced after Liuweiwuling treatment[1], it is possible that the increased liver regeneration in the Liuweiwuling-treated mice is a consequence of the reduced liver injury and does not reflect a direct effect of the intervention on liver regeneration process. To better support the argument that Liuweiwuling directly promotes liver regeneration after APAP overdose, any inference with the injury process needs to be avoided and treatment needs to be started after the peak of injury.

In summary, although the protective effect of Liuweiwuling tablets against APAP hepatotoxicity is interesting and was convincingly demonstrated, the proposed protective mechanism is questionable. The reduced inflammatory response and the increased liver regeneration by Liuweiwuling treatment is more likely a secondary effect of the protection by inhibition of metabolic activation of APAP rather than the primary mechanism of protection. Studies with natural products need to be carefully designed and consider all aspects of the mechanism of APAP-induced cell death in order to obtain relevant information on the therapeutic potential and mechanism of action of the product.

**REFERENCES**

1 **Lei YC**, Li W, Luo P. Liuweiwuling tablets attenuate acetaminophen-induced acute liver injury and promote liver regeneration in mice. *World J Gastroenterol* 2015; **21**: 8089-8095 [PMID: 26185380 DOI: 10.3748/wjg.v21.i26.8089]

2 **Jaeschke H**, Williams CD, Ramachandran A, Bajt ML. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. *Liver Int* 2012; **32**: 8-20 [PMID: 21745276 DOI: 10.1111/j.1478-3231.2011.02501.x]

3 **Antoine DJ**, Jenkins RE, Dear JW, Williams DP, McGill MR, Sharpe MR, Craig DG, Simpson KJ, Jaeschke H, Park BK. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. *J Hepatol* 2012; **56**: 1070-1079 [PMID: 22266604 DOI: 10.1016/j.jhep.2011.12.019]

4 **Chen GY**, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. *Science* 2009; **323**: 1722-1725 [PMID: 19264983 DOI: 10.1126/science.1168988]

5 **Antoine DJ**, Williams DP, Kipar A, Laverty H, Park BK. Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. *Mol Med* 2010; **16**: 479-490 [PMID: 20811657 DOI: 10.2119/molmed.2010.00126]

6 **Scaffidi P**, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature* 2002; **418**: 191-195 [PMID: 12110890]

7 **Ishida Y**, Kondo T, Tsuneyama K, Lu P, Takayasu T, Mukaida N. The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice. *J Leukoc Biol* 2004; **75**: 59-67 [PMID: 14557383]

8 **Yang R**, Zhang S, Kajander H, Zhu S, Koskinen ML, Tenhunen J. Ringer's lactate improves liver recovery in a murine model of acetaminophen toxicity. *BMC Gastroenterol* 2011; **11**: 125 [PMID: 22085740 DOI: 10.1186/1471-230X-11-125]

9 **Boess F**, Bopst M, Althaus R, Polsky S, Cohen SD, Eugster HP, Boelsterli UA. Acetaminophen hepatotoxicity in tumor necrosis factor/lymphotoxin-alpha gene knockout mice. *Hepatology* 1998; **27**: 1021-1029 [PMID: 9537442]

10 **Chiu H**, Gardner CR, Dambach DM, Durham SK, Brittingham JA, Laskin JD, Laskin DL. Role of tumor necrosis factor receptor 1 (p55) in hepatocyte proliferation during acetaminophen-induced toxicity in mice. *Toxicol Appl Pharmacol* 2003; **193**: 218-227 [PMID: 14644624]

11 **Williams CD**, Farhood A, Jaeschke H. Role of caspase-1 and interleukin-1beta in acetaminophen-induced hepatic inflammation and liver injury. *Toxicol Appl Pharmacol* 2010; **247**: 169-178 [PMID: 20637792 DOI: 10.1016/j.taap.2010.07.004]

12 **Williams CD**, Antoine DJ, Shaw PJ, Benson C, Farhood A, Williams DP, Kanneganti TD, Park BK, Jaeschke H. Role of the Nalp3 inflammasome in acetaminophen-induced sterile inflammation and liver injury. *Toxicol Appl Pharmacol* 2011; **252**: 289-297 [PMID: 21396389 DOI: 10.1016/j.taap.2011.03.001]

13 **Williams CD**, Bajt ML, Sharpe MR, McGill MR, Farhood A, Jaeschke H. Neutrophil activation during acetaminophen hepatotoxicity and repair in mice and humans. *Toxicol Appl Pharmacol* 2014; **275**: 122-133 [PMID: 24440789 DOI: 10.1016/j.taap.2014.01.004]

14 **Jaeschke H**. Mechanisms of Liver Injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. *Am J Physiol Gastrointest Liver Physiol* 2006; **290**: G1083-G1088 [PMID: 16687579]

15 **Jaeschke H**, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. *Drug Metab Rev* 2012; **44**: 88-106 [PMID: 22229890 DOI: 10.3109/03602532.2011.602688]

16 **Jaeschke H**, McGill MR, Williams CD, Ramachandran A. Current issues with acetaminophen hepatotoxicity--a clinically relevant model to test the efficacy of natural products. *Life Sci* 2011; **88**: 737-745 [PMID: 21296090 DOI: 10.1016/j.lfs.2011.01.025]

17 **Williams CD**, Bajt ML, Farhood A, Jaeschke H. Acetaminophen-induced hepatic neutrophil accumulation and inflammatory liver injury in CD18-deficient mice. *Liver Int* 2010; **30**: 1280-1292 [PMID: 20500806 DOI: 10.1111/j.1478-3231.2010.02284.x]

18 **Liu HM**, Xu NN, Nie L. [Quality assessment of Liuwei Wuling tablet by HPLC fingerprint and quantitative analysis]. *Zhongguo Zhong Yao Za Zhi* 2014; **39**: 1816-1821 [PMID: 25282888]

19 **Jiang Y**, Fan X, Wang Y, Tan H, Chen P, Zeng H, Huang M, Bi H. Hepato-protective effects of six schisandra lignans on acetaminophen-induced liver injury are partially associated with the inhibition of CYP-mediated bioactivation. *Chem Biol Interact* 2015; **231**: 83-89 [PMID: 25753323 DOI: 10.1016/j.cbi.2015.02.022]

20 **Jaeschke H**, Williams CD, McGill MR, Xie Y, Ramachandran A. Models of drug-induced liver injury for evaluation of phytotherapeutics and other natural products. *Food Chem Toxicol* 2013; **55**: 279-289 [PMID: 23353004 DOI: 10.1016/j.fct.2012.12.063]

21 **Xie Y**, Williams CD, McGill MR, Lebofsky M, Ramachandran A, Jaeschke H. Purinergic receptor antagonist A438079 protects against acetaminophen-induced liver injury by inhibiting p450 isoenzymes, not by inflammasome activation. *Toxicol Sci* 2013; **131**: 325-335 [PMID: 22986947 DOI: 10.1093/toxsci/kfs283]

22 **Du K**, Williams CD, McGill MR, Xie Y, Farhood A, Vinken M, Jaeschke H. The gap junction inhibitor 2-aminoethoxy-diphenyl-borate protects against acetaminophen hepatotoxicity by inhibiting cytochrome P450 enzymes and c-jun N-terminal kinase activation. *Toxicol Appl Pharmacol* 2013; **273**: 484-491 [PMID: 24070586 DOI: 10.1016/j.taap.2013.09.010]

23 **Jaeschke H**, Du K. Benzyl Alcohol: A novel treatment for acetaminophen overdose? *Hepatology* 2015; **62**: 1641-1642 [PMID: 25777460 DOI: 10.1002/hep.27786]

24 **Bajt ML**, Knight TR, Farhood A, Jaeschke H. Scavenging peroxynitrite with glutathione promotes regeneration and enhances survival during acetaminophen-induced liver injury in mice. *J Pharmacol Exp Ther* 2003; **307**: 67-73 [PMID: 12954812]

25 **Bhushan B**, Walesky C, Manley M, Gallagher T, Borude P, Edwards G, Monga SP, Apte U. Pro-regenerative signaling after acetaminophen-induced acute liver injury in mice identified using a novel incremental dose model. *Am J Pathol* 2014; **184**: 3013-3025 [PMID: 25193591 DOI: 10.1016/j.ajpath.2014.07.019]

**P-Reviewer:** De Ponti F, Garcia-Fernandez MI, Julie NL **S-Editor:** Yu J

**L-Editor:** **E-Editor:**